Progress in Targeted Therapy for Lung Cancer: New Data Progress in Targeted Therapy for Lung Cancer: New Data
Dr Mark Kris explains why he is even more hopeful when it comes to targeted therapy for lung cancer after seeing several trial results presented during this year's virtual ASCO meeting.Medscape Oncology
Publication date: Available online 4 July 2020Source: European UrologyAuthor(s): Friedemann Krentel, Roland Seiler
This study is to distinguish peripheral lung cancer and pulmonary inflammatory pseudotumor using CT-radiomics features extracted from PET/CT images.
Conventional CTCS images the mid/lower chest for coronary artery disease (CAD). Because many CAD patients are also at risk for lung malignancy, CTCS often discovers incidental pulmonary nodules (IPN). CTCS exc...
Publication date: October 2020Source: Pharmacological Research, Volume 160Author(s): Shengda Luo, Jiahui Xu, Zebo Jiang, Lei Liu, Qibiao Wu, Elaine Lai-Han Leung, Alex Po Leung
Conclusion: We propose the ALK-BPI score as a new prognostic tool that can easily be applied for ALK-positive lung cancer patients with brain metastases in daily clinical practice, as it has at least the same prognostic value as Lung-molGPA.
Cell Death &Disease, Published online: 06 July 2020; doi:10.1038/s41419-020-2701-zPD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer
Gao Zhou Epidemiological studies have corroborated that respiratory diseases, including lung cancer, are related to fine particulate matter (<2.5 μm) (PM2.5) exposure. The toxic responses of PM2.5 are greatly influenced by the source of PM2.5. However, the effects of PM2.5 from Beijing on bronchial genotoxicity are scarce. In the present study, PM2.5 from Beijing was sampled and applied in vitro to investigate its genotoxicity and the mechanisms behind it. Human bronchial epithelial cells 16HBE were used as a model for exposure. Low (67.5 μg/mL), medium (116.9 μg/mL), and high (202.5 &...
Abstract Dihydroberberine (DHBER), the partially reduced form of the alkaloid berberine (BER), is known to exhibit important biological activities. Despite this fact, there have been only few studies that concern the biological properties of functionalized DHBER. Attracted by the potentiality of this latter compound, we have realized the preparation of new arylhydrazono-functionalized DHBERs, starting from BER and some α-bromohydrazones. On the other hand, also the fully reduced form of BER, namely tetrahydroberberine (THBER), and its derivatives have proven to present different biological activities. Therefore, the ...
Ferrante Enrico, Pontrelli Giuseppe, Trimboli MicheleNeurology India 2020 68(3):706-707
Publication date: Available online 4 July 2020Source: Molecular ImmunologyAuthor(s): Dehai Che, Shuai Zhang, Zihan Jing, Lihua Shang, Shi Jin, Fang Liu, Jing Shen, Yue Li, Jing Hu, Qingwei Meng, Yan Yu